Loading…
EWTX
Edgewise Therapeutics, Inc.
NASDAQ· Healthcare· Biotechnology
$42.76-3.24%
Key metrics
- Market cap
- $4.64B
- P/E
- —
- Forward P/E
- —
- P/B
- 10.3x
- Dividend yield
- —
- EPS
- -$1.79
- ROE
- -38.03%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.33
- 52-week high
- $48.40
- 52-week low
- $13.69
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
- 127
- Boulder, United States
Company description provided by Yahoo Finance.